# PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

Study · id `cardio:ct-nct05419193` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05419193](<https://clinicaltrials.gov/study/NCT05419193>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05419193

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

## Technical summary

Registry record NCT05419193. Randomized; single masking; primary purpose treatment. Start 2023-02-21 (actual); primary completion 2024-12-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 168 participants (enrolled count; ClinicalTrials.gov record NCT05419193, source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)
- Started: 2023-02-21 (actual) (ClinicalTrials.gov record NCT05419193, source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)
- Primary completion: 2024-12-18 (actual) (ClinicalTrials.gov record NCT05419193, source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)
- Completion: 2025-03-11 (actual) (ClinicalTrials.gov record NCT05419193, source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05419193, source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05419193-2025-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
- Acronym: PRO-CHASE
- Condition: Stroke
- Condition: Vascular Accident
- Condition: Intracranial Hemorrhages
- Condition: Intracerebral Hemorrhage
- Condition: Hemorrhagic Stroke
- Condition: Stroke, Acute
- Intervention (Drug): Propranolol Hydrochloride
- Intervention (Other): control group
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Propranolol (`cardio:propranolol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 17a7aecbfeea2bdaadab54fe9a3715a77cfeac3791e7311d53146aeee9b07453
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
